Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Quintiles to Start COPD Management Services
October 5, 2009
- Hoyu Acquires 4 Kracie Group Companies
October 5, 2009
- DSP Starts Shipping New Amlodin OD Tab Produced Using SUITAB-NEX Technology
October 5, 2009
- Patient Recognition Criteria Approved for 11 Designated Diseases
October 5, 2009
- NEW PRODUCTS
October 5, 2009
- Mirtazapine Shows Fast, Long-Lasting Effects: Prof. Kinoshita
October 5, 2009
- Team Nagatsuma Sets Out
October 5, 2009
- TOPICS／Dr Karasawa Intends to Lead JMA for Another Term of Office
October 5, 2009
- Discussions on NHI Drug Pricing System Reform Remain Halted at Chuikyo
October 5, 2009
- PMS Activities Put Additional Burden on Doctors
October 5, 2009
- Price Gaps Remain Unchanged for Drugs Priced by Similar Efficacy Comparison Method
October 5, 2009
- Fixed-Dose Combination Drugs Should Be Priced at 10-30% of the Sum of Prices of Combined Drugs: Korosho
October 5, 2009
- Term of Office to Expire for 6 of 7 Chuikyo Members Representing Healthcare Providers
October 5, 2009
- Measures to Promote Development of Unapproved Drugs Proposed by Industry
October 5, 2009
- REGULATORY NEWS IN BRIEF
October 5, 2009
- SURVEY／60% of Doctors Voted for DPJ Because of Frustration with LDP
October 5, 2009
- Biomarker Science to Develop Alternative Therapy for Heart Transplantation
October 5, 2009
- JPMA to Disclose More Information on Clinical Studies
October 5, 2009
- Kenporen Records Second-Largest Deficit in FY2008
October 5, 2009
- JPMA Studies How to Support Bioventures
October 5, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…